Interview with Congruity CEO Justin Davis

Generic-drug approval growth doesn't spark competition

https://ift.tt/2PQB7te
The first three generics introduced make the biggest dent on prices. But the vast majority of generic-drug approvals from 2012 to 2017 were for the fourth, fifth, sixth or even later versions that minimally impact prices, according to a new report.


from Verdure http://bit.ly/2U8KfHZ

Comments